KR920703121A - 진단 약제로서의 항응고제의 용도 - Google Patents
진단 약제로서의 항응고제의 용도Info
- Publication number
- KR920703121A KR920703121A KR1019920701497A KR920701497A KR920703121A KR 920703121 A KR920703121 A KR 920703121A KR 1019920701497 A KR1019920701497 A KR 1019920701497A KR 920701497 A KR920701497 A KR 920701497A KR 920703121 A KR920703121 A KR 920703121A
- Authority
- KR
- South Korea
- Prior art keywords
- polypeptide
- anticoagulant
- vac
- medicament
- anticoagulant polypeptide
- Prior art date
Links
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 18
- 229940127219 anticoagulant drug Drugs 0.000 title claims abstract description 18
- 239000000032 diagnostic agent Substances 0.000 title claims description 3
- 229940039227 diagnostic agent Drugs 0.000 title claims description 3
- 229920001184 polypeptide Polymers 0.000 claims abstract 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 20
- 102000000412 Annexin Human genes 0.000 claims abstract 5
- 108050008874 Annexin Proteins 0.000 claims abstract 5
- 230000005298 paramagnetic effect Effects 0.000 claims abstract 3
- 239000004475 Arginine Substances 0.000 claims abstract 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000002872 contrast media Substances 0.000 claims abstract 2
- 229960002897 heparin Drugs 0.000 claims abstract 2
- 229920000669 heparin Polymers 0.000 claims abstract 2
- 239000008363 phosphate buffer Substances 0.000 claims abstract 2
- 239000002504 physiological saline solution Substances 0.000 claims abstract 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract 2
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract 2
- -1 fluorescein isothiocyanates Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 102100027378 Prothrombin Human genes 0.000 claims 2
- 108010094028 Prothrombin Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002439 hemostatic effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 229940039716 prothrombin Drugs 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000005291 magnetic effect Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 1
- 229910052753 mercury Inorganic materials 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052713 technetium Inorganic materials 0.000 claims 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims 1
- 229910052716 thallium Inorganic materials 0.000 claims 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 239000002506 anticoagulant protein Substances 0.000 abstract 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 description 11
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 9
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 8
- 150000003904 phospholipids Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 3
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4718—Lipocortins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/04—Phospholipids, i.e. phosphoglycerides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Dental Preparations (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- External Artificial Organs (AREA)
- Peptides Or Proteins (AREA)
Abstract
내용 없음
Description
진단 약제로서의 항응고제의 용도
[도면의 간단한 설명]
제1도:Ca 농도의 증감에 따른 인지질에 대한 VAC의 흡착 및 탈착의 변화를 나타낸 것이다. 20% DOPS/80% DOPC 인지질 이중층에 대한 VAC(1μg/ml)의 흡착이다. Ca2+(3,4,6mM)의 적가는 ↑ 또는 △로 나타내었다.
제2도:인지질 표면에 대한 VAC의 흡착에 대하여 인지질 조성 및 Ca2+농도의 영향에 대한 것이다. ○100% DOPS; ●20%DOPS; △5%DOPS; □1%DOPS; ◇100%DOPC; 모든 혼합물은 DOPC를 나머지를 보충하였다.[VAC]=1μg/ml.
제3도:VAC의 흡착에 대한 이가 이온의 효과에 관한 것이다. 특정이온(1 또는 3mM)의 존재하에서 20%DOPS 및 80%DOPC의 이중층에 대한 VAC흡착이다.[VAC]=1μg/ml,
제4도:인지질 표면에 대한 VAC의 Ca2+-의존성 흡착에 대한 Zn2+의 상승효과에 관한 것이다. 5μM Zn2+의 존재하에서 1%DOPS 및 99% DOPC에 대한 VAC흡착에서의 Ca2+의 효과가 측정되었다. [VAC]=1μg/ml,
제5도:조성을 변화시킨 인지질 이중층에 대한 VAC의 흡착에 관한 것이다. 순수하거나 80% 디올레오일 포스파티딜 콜린(DOPC)과 혼합되거나 한 디올레오릴 포스파티딜 세린(DOPS), 카디올리핀(CL) 및 디올레오일 포스파티딜 에탄올아민(DOPE)에 대한 VAC흡착, 80% DOPC와 혼합된 디올레오일 포스파티딜 글리세롤(DOPG), 포스파티딜 이노시톨(PI) 및 스테아릴아민에 대한 VAC흡착 또는 순수한 DOPC에 대한 VAC흡착에 관한 것이다. [VAC]=1μg/ml, [Ca2+]=3mM.
제6도:1,3,4,6-테트라클로로-3α-6α-디페닐글리콜우릴(IODO-GEN)의 도식이다.
제7도:1 내지 2분출물의 방사능 분포이다.
제8도:선상 분석기에서의 방사능 분포이다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (24)
- 감지할 수 있는 표지를 갖는 것을 특징으로 하는 아넥신군의 항응고 폴리펩타이드.
- 제1항에 있어서, 항응고 폴리펩타이드가 VAC임을 특징으로 하는 항응고 폴리펩타이드.
- 제1항 내지 제2항중의 어느 하나에 있어서, 감지할 수 있는 표지로서 형광표지, 바람직하게는 플루오레세인 이소티오시아네이트, 할로겐, 테크네튬, 납, 수은, 탈륨 또는 인듐의 방사능 동위원소, 특히 바람지하게는 1311또는 1251, 또는 상자기 조영제를 사용함을 특징으로 하는 항응고 폴리펩타이드.
- 포스파티딜 세린을 포스파티딜 콜린으로부터 구별하기 위한 상기 특허청구항 중의 어느 하나에 따르는 항응고 폴리펩타이드.
- 진단약제로의 사용을 위한 상기 특허청구항 중의 어느 하나에 따르는 항응고 폴리펩타이드.
- a) 감지할 수 있는 표지를 가진 아넥신 군의 항응고 폴리펩타이드를 시스템에 도입하고, b) 잠복기간 후에 상술된 폴리펩타이드의 분포를 관찰함을 특징으로 하는 지혈시스템의 활성 출발점을 검출하는 방법.
- 제5항에 있어서, 폴리펩타이드가 VAC임을 특징으로 하는 방법.
- 제5항 내지 제7항중의 어느 하나에 있어서, 방사성 동위원소, 바람직하게는 125T,123I,131I,111In,991mIc,203pb,198Hg또는 201T1방사성 동위원소중의 하나가 사용되거나 상자기 조영 원소가 사용되는 것을 특징으로 하는 방법.
- 제5항 내지 제8항중의 어느 하나에 있어서, 폴리펩타이드를 동맥내 또는 정맥내 경로로 투여함을 특징으로 하는 방법.
- 제5항 내지 제9항중의 어느 하나에 있어서. 상술된 폴리펩타이드의 분포를 감마 섬광 카메라 또는 자기공명 측정법을 사용하여 체외적으로 관찰함을 특징으로 하는 방법.
- (a) 시험될 혈액을 감지할 수 있는 표지를 가진 아넥신계 항응고 폴리펩타이드와 체외적으로 혼합하고,
- (b) 특정 형태의 세포와 결합된 표지를 분석함을 특징으로 하여 프로트롬빈 상태를 감지하는 방법.
- 제11항에 있어서, 폴리펩타이드가 VAC임은 특징으로 하는 방법.
- 제11항 내지 제12항중의 어느 하나에 있어서, 김지할 수 있는 표지로 플루오레세인 그룹, 방사선 동위원소, 바람직하게는 125I, 123I,131I,111In,99mIc,203Pb,198Hg또는 201T1동위원소중 하나가 사용됨을 특징으로 하는 방법.
- 감지할 수 있는 표지를 가진 아넥신계 항응고 폴리펩타이드 이외에 보조제를 포함함을 특징으로 하는 약제.
- 제14항에 있어서, 폴리펩타이드가 VAC임을 특징으로 하는 약제.
- 제14항 또는 제15항중에 있어서, 생리식염용액, 트윈 80, 아르기닌 및/또는 인산염 완충액이 보조제로 사용됨을 특징으로 하는 약제.
- 제14항 내지 제16항중의 어느 하나에 있어서, 혈장 칼륨 농도를 감소시키지 않는 항응고제, 바람직하게는 헤파린은 부가적으로 사용함을 특징으로 하는 약제.
- 진단약제로 사용하기 위한 제16항 내지 제17항중의 어느 하나에 따른 약제.
- 제6항 내지 제13항중의 어느 하나에 있어서, 항응고 폴리펩타이드 대신에 제14항 내지 제17항중의 어느 하나에 따르는 약제중 하나를 사용함을 특징으로 하는 방법.
- 포스파티딜 세린을 포스파티딜 콜린으로부터 구별할 수 있는 제14항 내지 제17항중의 어느 하나에 따른 약제 또는 제1항 내지 제3항중의 어느 하나에 따른 항응고 폴리펩타이드를 함유하는, 지혈 시스템 및/또는 혈전의 프로트롬빈 상태 또는 활성 출발점을 진단 감지하기 위한 세트.
- 포스파티틸 세린을 포스파티틸 콜린으로부터 구별하기 위한, 제1항 내지 제3항중의 어느 하나에 따른 항응고 폴리펩타이드 또는 제14항 내지 제17항중의 어느 하나에 따른 약제의 용도.
- 지혈 시스템 또는 혈전의 포로트롬빈 상태 또는 장애의 출발점을 진단하기 위한 제1항 내지 제3항중의 어느 하나에 따른 항응고 폴리펩타이드 또는 제14항 내지 제17항중의 어느 하나에 따른 약제의 용도.
- ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP3942988.1 | 1989-12-27 | ||
| DE3942988 | 1989-12-27 | ||
| PCT/EP1990/002257 WO1991009628A1 (de) | 1989-12-27 | 1990-12-19 | Verwendung eines antikoagulant als diagnostikum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR920703121A true KR920703121A (ko) | 1992-12-17 |
| KR0181520B1 KR0181520B1 (ko) | 1999-05-01 |
Family
ID=6396455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920701497A KR0181520B1 (ko) | 1989-12-27 | 1990-12-19 | 항응고제를 함유하는 진단용 조성물 |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP0806670B1 (ko) |
| JP (1) | JP3135261B2 (ko) |
| KR (1) | KR0181520B1 (ko) |
| AT (2) | ATE429644T1 (ko) |
| AU (1) | AU642202B2 (ko) |
| CA (1) | CA2070647C (ko) |
| DE (3) | DE4040817A1 (ko) |
| ES (1) | ES2113372T3 (ko) |
| FI (1) | FI107586B (ko) |
| HU (2) | HU209650B (ko) |
| NO (1) | NO305276B1 (ko) |
| NZ (1) | NZ236620A (ko) |
| PT (1) | PT96385B (ko) |
| WO (1) | WO1991009628A1 (ko) |
| ZA (1) | ZA9010319B (ko) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5627036A (en) * | 1989-12-27 | 1997-05-06 | Boehringer Ingelheim International Gmbh | Use of an anticoagulant as a diagnostic agent |
| ATE210464T1 (de) * | 1992-06-09 | 2001-12-15 | Neorx Corp | BIOTIN-DOTA KONJUGATE UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN |
| AU1186295A (en) * | 1993-11-24 | 1995-06-13 | University Of Washington | Blood coagulation retardants and devices |
| JP3664727B2 (ja) * | 1994-01-24 | 2005-06-29 | ネオルクス コーポレイション | 放射標識したアネキシン |
| US5968477A (en) * | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
| US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
| EP0763056B1 (en) * | 1994-03-16 | 2000-08-09 | Mallinckrodt Inc. | Use of surfactants for stabilization of peptides and proteins for radiopharmaceutical use |
| ATE160875T1 (de) * | 1994-04-11 | 1997-12-15 | Nexins Research B V | Verfahren zum nachweis und/oder zur bestimmung und/oder zur isolierung von apoptotischen zellen in oder aus einer probe |
| EP0765166B1 (en) * | 1994-06-16 | 2003-05-21 | Neorx Corporation | Radiolabeled annexin-galactose conjugates |
| CA2185349C (en) * | 1994-06-16 | 2010-04-20 | John M. Reno | Radiolabeled annexin-galactose conjugates |
| EP1486509A3 (en) * | 1994-12-07 | 2005-03-23 | Neorx Corporation | Radiolabeled annexin-galactose cluster conjugates |
| EP0799050B1 (en) * | 1994-12-07 | 2004-08-11 | Neorx Corporation | Radiolabeled annexin-galactose cluster conjugates |
| US5886143A (en) * | 1994-12-07 | 1999-03-23 | Neorx Corporation | Hepatic-directed compounds and reagents for preparation thereof |
| US5955605A (en) * | 1995-02-21 | 1999-09-21 | Neorx Corporation | Biotinidase resistant biotin-DOTA conjugates |
| FR2736197B1 (fr) * | 1995-06-29 | 1997-09-12 | Univ Paris Curie | Nanoparticules magnetiques couplees a de l'annexine et leur utilisation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4455290A (en) * | 1981-04-02 | 1984-06-19 | Research Corporation | Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1 |
| US4427646A (en) * | 1981-04-02 | 1984-01-24 | Research Corporation | Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo |
| US4820505A (en) * | 1985-04-04 | 1989-04-11 | Scripps Clinic And Research Foundation | Detection of activated platelets with antibodies to thrombospondin |
| PT87083B (pt) * | 1987-03-28 | 1992-07-31 | Boehringer Ingelheim Int | Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem |
| DE3810331A1 (de) * | 1988-03-26 | 1989-10-05 | Boehringer Ingelheim Int | Monoklonale vac-antikoerper |
-
1990
- 1990-12-19 AU AU70711/91A patent/AU642202B2/en not_active Expired
- 1990-12-19 EP EP97113801A patent/EP0806670B1/de not_active Expired - Lifetime
- 1990-12-19 CA CA002070647A patent/CA2070647C/en not_active Expired - Lifetime
- 1990-12-19 ES ES91902118T patent/ES2113372T3/es not_active Expired - Lifetime
- 1990-12-19 WO PCT/EP1990/002257 patent/WO1991009628A1/de active IP Right Grant
- 1990-12-19 AT AT97113801T patent/ATE429644T1/de not_active IP Right Cessation
- 1990-12-19 KR KR1019920701497A patent/KR0181520B1/ko not_active IP Right Cessation
- 1990-12-19 JP JP03502409A patent/JP3135261B2/ja not_active Expired - Lifetime
- 1990-12-19 DE DE4040817A patent/DE4040817A1/de not_active Withdrawn
- 1990-12-19 DE DE59010946T patent/DE59010946D1/de not_active Expired - Lifetime
- 1990-12-19 HU HU9202149A patent/HU209650B/hu unknown
- 1990-12-19 AT AT91902118T patent/ATE164083T1/de not_active IP Right Cessation
- 1990-12-19 DE DE59010815T patent/DE59010815D1/de not_active Expired - Lifetime
- 1990-12-19 EP EP91902118A patent/EP0509026B1/de not_active Expired - Lifetime
- 1990-12-19 HU HU9202149A patent/HUT61491A/hu unknown
- 1990-12-21 NZ NZ236620A patent/NZ236620A/en unknown
- 1990-12-21 ZA ZA9010319A patent/ZA9010319B/xx unknown
- 1990-12-27 PT PT96385A patent/PT96385B/pt not_active IP Right Cessation
-
1992
- 1992-06-12 FI FI922719A patent/FI107586B/fi active
- 1992-06-26 NO NO922528A patent/NO305276B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2070647C (en) | 2001-04-10 |
| DE4040817A1 (de) | 1991-07-04 |
| AU642202B2 (en) | 1993-10-14 |
| KR0181520B1 (ko) | 1999-05-01 |
| PT96385B (pt) | 1998-06-30 |
| NO922528D0 (no) | 1992-06-26 |
| NZ236620A (en) | 1997-03-24 |
| EP0806670A3 (de) | 1997-12-10 |
| PT96385A (pt) | 1991-10-31 |
| EP0806670B1 (de) | 2009-04-22 |
| CA2070647A1 (en) | 1991-06-28 |
| WO1991009628A1 (de) | 1991-07-11 |
| DE59010946D1 (de) | 2009-06-04 |
| NO922528L (no) | 1992-08-26 |
| EP0509026B1 (de) | 1998-03-18 |
| FI922719A0 (fi) | 1992-06-12 |
| AU7071191A (en) | 1991-07-24 |
| HU9202149D0 (en) | 1992-10-28 |
| HU209650B (en) | 1994-09-28 |
| ES2113372T3 (es) | 1998-05-01 |
| DE59010815D1 (de) | 1998-04-23 |
| JP3135261B2 (ja) | 2001-02-13 |
| ATE164083T1 (de) | 1998-04-15 |
| ZA9010319B (en) | 1992-08-26 |
| FI107586B (fi) | 2001-09-14 |
| EP0806670A2 (de) | 1997-11-12 |
| HUT61491A (en) | 1993-01-28 |
| NO305276B1 (no) | 1999-05-03 |
| ATE429644T1 (de) | 2009-05-15 |
| JPH05502877A (ja) | 1993-05-20 |
| EP0509026A1 (de) | 1992-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920703121A (ko) | 진단 약제로서의 항응고제의 용도 | |
| Triplett et al. | A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification | |
| Von Wichert et al. | Bronchoalveolar lavage | |
| Kimmich et al. | A Na+-independent, phloretin-sensitive monosaccharide transport system in isolated intestinal epithelial cells | |
| Law | Vascular permeability and late radiation fibrosis in mouse lung | |
| Apt et al. | Idiopathic pulmonary hemosiderosis. A study of the anemia and iron distribution using radioiron and radiochromium | |
| Wheeler et al. | Role of Na+ in the transport of amino acids in rabbit red cells | |
| Mookerjee et al. | The effects of cytochalasins on lymphocytes. Identification of distinct cytochalasin-binding sites in relation to mitogenic response and hexose transport. | |
| Nilsson et al. | In vivo recovery of factor VIII: A comparison of one-stage and two-stage assay methods | |
| US6284475B1 (en) | Assays for diagnosis of thrombophilic disease | |
| Giles et al. | Studies of factors V and VIII: C in an animal model of disseminated intravascular coagulation. | |
| Hom et al. | The vitamin B12 binding capacity of transcobalamin I and II of normal human serum | |
| Parker et al. | Hematologic improvement in a patient with gaucher disease on long‐term enzyme replacement therapy: Evidence for decreased splenic sequestration and improved red blood cell survival | |
| Levine | The effect of thrombocytopenia on the determination of platelet aggregation | |
| Pettegrew et al. | Membrane biophysical studies of lymphocytes and erythrocytes in manic-depressive illness | |
| ES2372810T3 (es) | Método para medir la activación de leucocitos. | |
| Zucker et al. | Microelectrophoresis of washed and unwashed human blood platelets, with additional studies of platelets from patients with von Willebrand’s disease and thrombasthenia | |
| Ebbe et al. | Platelet survival in the rat as measured with tritium-labeled diisopropylfluorophosphate | |
| PETERS et al. | Platelet kinetics in congenital heart disease | |
| Ben-Nun et al. | Cystine loading induces Fanconi's syndrome in rats: in vivo and vesicle studies | |
| Cooney et al. | The use of 32di-isopropylfluorophosphate (32DFP) as a platelet label: Evidence for reutilization of this isotope in man | |
| Azuma et al. | Platelet aggregation caused by a partially purified jellyfish toxin from Carybdea rastonii | |
| Johnson | Platelets in hemostasis | |
| Guggenheim et al. | The preparation and characterization of mitochondria from developing red blood cells | |
| Tyan | Old mice: Marrow response to bleeding or endotoxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20101129 Year of fee payment: 13 |
|
| EXPY | Expiration of term |